LPTX实时信号 | 通过Getagraph.com最大化利润

出售 119992 min ago

@ $3.52

发出时间: 9 Feb 2024 @ 03:59

回报率: -7.10%

上一信号: Feb 8 - 04:44

上一信号: 购买

回报率: 2.03 %

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 04:00):

Stats
今日成交量	151 390
平均成交量	313 747
市值	83.72M
EPS	$0 ( 2024-03-22 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.820
ATR14	$0.0250 (0.77%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-10	Gilead Sciences, Inc.	Sell	0	Common Stock
2024-01-29	Mashiach Nissim	Buy	25 000	Stock Option (Right to Buy)
2024-01-29	Dietz Thomas John	Buy	30 000	Stock Option (Right to Buy)
2024-01-29	Schilsky Richard	Buy	25 000	Stock Option (Right to Buy)
2024-01-29	Granfield Christine	Buy	85 000	Employee Stock Option (Right to Buy)

INSIDER POWER
66.50
Last 95 transactions
Buy: 10 825 606 \| Sell: 1 768 106

音量相关性

長: 0.22 (neutral)

短: -0.08 (neutral)

Signal:(48.669) Neutral

Leap Therapeutics Inc 相关性

10 最正相关
LPCN	0.922
EWTX	0.919
CNDT	0.917
SRAX	0.915
CPIX	0.911
NESR	0.909
RPAY	0.905
VTRS	0.903
HNNA	0.9
SMSI	0.899

10 最负相关
CNCE	-0.851
CNST	-0.84
TYHT	-0.838
UNCY	-0.828
ALR	-0.821
EPZM	-0.819
PSACU	-0.817
BTBD	-0.811
VERX	-0.81
DRNA	-0.809

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Leap Therapeutics Inc 相关性 - 货币/商品

0.63
( weak )

0.48
( neutral )

0.00
( neutral )

0.56
( weak )

-0.60
( weak negative )

Leap Therapeutics Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-427 000 (0.00 %)
EPS:	$-3.98

FY	2023
营收:	$0
毛利润:	$-427 000 (0.00 %)
EPS:	$-3.98

FY	2022
营收:	$0
毛利润:	$-415 000 (0.00 %)
EPS:	$-4.82

FY	2021
营收:	$1.50M
毛利润:	$1.50M (100.00 %)
EPS:	$-0.470

Financial Reports:

No articles found.

Leap Therapeutics Inc

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.